Trials / Completed
CompletedNCT00259753
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- OPKO Health, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevasiranib |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2005-12-01
- Last updated
- 2008-08-05
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00259753. Inclusion in this directory is not an endorsement.